Tr1X-preview

Tr1x

Tr1X

Private

San Diego, CaliforniaHealthcare & Life Scienceshttps://www.tr1x.bio

Last Round

VC Round

Oct 14, 2025

Total Funding Raised

$87M

Momentum Score

25 /100

Company Overview

Tr1x is a biotechnology company specializing in cell therapies for the treatment of autoimmune disorders, utilizing advancements in genetic engineering and T-cell biology to create scalable and effective cellular cures that target inflammation and autoimmunity, ultimately transforming patient lives.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Usage-Based SaaS, Government Contracts

AI Layer

Non-AI

Keywords

allogeneic cell therapyTreg cell therapyoff-the-shelf cell therapyCAR-Treg cell therapyTr1 cellsautoimmune disease therapyGraft-versus-Host DiseaseGvHDimmune resetinflammatory disease therapyclinical-stage biotechmultiple sclerosis therapyinflammatory bowel disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tr1X Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Tr1X Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
VC Round	Oct 14, 2025
Grant	Apr 4, 2025
Series A	Jan 17, 2024

View all Funding Rounds

Key People

Founding team and executive leadership

David de Vries

Co-Founder Chief Operating Officer

Founding Team

Tr1X Investors

Notable investors and investment history

Investor	Rounds
The Column Group	VC Round, Series A
Neva SGR	Series A, VC Round
The Chernin Group	Series A
California Institute for Regenerative Medicine	Grant
Alexandria Venture Investments	Series A, VC Round

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 27, 2026
New data on Engineered Tr1 Treg cell therapies to be presented at ASGCT 2026.
Apr 27, 2026
Two oral presentations at ASGCT Annual Meeting 2026 in Boston.

View all signals

Tr1X Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Tr1X Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tr1X's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California

Employee Range44

Year Founded2018

Last FundingOct 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.